(1.30%) 5 129.81 points
(1.27%) 38 712 points
(2.01%) 16 159 points
(-0.80%) $78.32
(5.31%) $2.14
(0.06%) $2 310.90
(-0.38%) $26.73
(0.40%) $966.45
(-0.35%) $0.929
(-1.22%) $10.86
(-0.09%) $0.797
(0.37%) $91.47
5 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 6.06%
Live Chart Being Loaded With Signals
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins...
Stats | |
---|---|
今日成交量 | 10 402.00 |
平均成交量 | 22 179.00 |
市值 | 41.91M |
EPS | $0 ( 2024-03-28 ) |
下一个收益日期 | ( $-0.0700 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.97 |
ATR14 | $0.0260 (1.82%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Lucy Patrick K. | Buy | 13 125 | Stock Option |
2024-04-11 | Tarnok Michael P. | Sell | 13 125 | Stock Option |
2024-04-11 | Hazelton Joseph P | Buy | 20 000 | Stock Option |
2024-03-13 | Hazelton Joseph P | Buy | 41 720 | Common Stock |
2024-03-13 | Emalfarb Mark A | Buy | 124 454 | Common Stock |
INSIDER POWER |
---|
81.62 |
Last 99 transactions |
Buy: 3 507 936 | Sell: 1 014 811 |
Dyadic International Inc 财务报表
Annual | 2023 |
营收: | $2.90M |
毛利润: | $922 957 (31.84 %) |
EPS: | $-0.240 |
FY | 2023 |
营收: | $2.90M |
毛利润: | $922 957 (31.84 %) |
EPS: | $-0.240 |
FY | 2022 |
营收: | $2.93M |
毛利润: | $807 110 (27.54 %) |
EPS: | $-0.330 |
FY | 2021 |
营收: | $2.40M |
毛利润: | $459 393 (19.11 %) |
EPS: | $-0.470 |
Financial Reports:
No articles found.
Dyadic International Inc
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。